Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week

Inclusion Criteria: * HIV-1 infection, coinfection HIV-1/HIV-2 possible * Age≥18 years old * Current dual therapy unchanged for the last 6 months with Dolutegravir/ Lamivudine or Dolutegravir / Rilpivirine or Darunavir/r / Lamivudine * If a genotype is available in the patient medical history; virus must be susceptible to all on going dual therapy. If no ARN genotype available, the patients can be included in the study * Viral load (VL) \< 50 c/mL in the past twelve months, with at least 3 VL measurements including screening; only one blip \< 200 c/mL is authorized in the 6-12 previous months * CD4 T cells \> 250/mm3 at W-4 * Estimated glomerular filtration rate \> 60 mL/min (CKD-EPI method) * AST et ALT \< 3N * Haemoglobin \> 10 g/dL * Platelets \> 100 000/mm3 * For women of childbearing age, negative pregnancy plasmatic test at W-4 and agree to use efficacy contraception during the study * Commitment to use condom prevention and protection during sexual intercourse for the duration of the trial. * Social security system coverage (including State Medical Aid-AME, if EC approves it) * Informed consent form signed Exclusion Criteria: * Infection by HIV-2 * Chronic and active Viral B Hepatitis with positive antigen HBs * Chronic and active Viral C Hepatitis with treatment expected in the next 48 weeks * Concomitant treatment using interferon, interleukins, any other immune-therapy or chemotherapy, antivitamin K+ with co-treatment by booster * Concomitant prophylactic or curative treatment for an opportunistic infection * All conditions (use of alcohol, drugs, etc.) judged by the investigator to possibly interfere with study protocol compliance, observance and/or study treatment tolerance * Pregnant or breast feeding women * Subjects under "sauvegarde de justice" (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship